retatrutide phase 2 results weight loss with as compared to currently licenced obesity 🚨Breaking: Retatrutide's first Phase 3

doi: 10.1210/endo.137.9.8756537

Suboptimal dosing : Patients may be on a dose intended for diabetes management (0.5-1.0 mg weekly) rather than the higher dose approved for weight loss (2.4 mg weekly)

Instead, they launched the most aggressive product imaginable, forced the FDA into a public response, and that response covers all GLP-1 APIs, including the injectables they were happily selling without scrutiny

doi: 10.1073/pnas.0305930101

Eligibility is determined through licensed medical evaluation conducted via telehealth under physician supervision

Consuming a meal or snack containing protein and carbohydrates before and after exercise can help maximize muscle protein synthesis and recovery